Supply Tacrolimus Hydrate/Tsukubaenolide Hydrate/Tacrolimus Monohydrate/Tacrolimus CAS 109581-93-3

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: HMJ- Tacrolimus Hydrate
• Color: White
• Melting Point: 113-115
• Storage: Sealed in Dry, 2-8°c
• Test: HPLC
• Weight: 804.02
• CAS: 104987-11-3
• Shelf Life: 2 Years
• Grade: Pharmaceutical Grade
• Transport Package: Ziplock Foil Bag. Drum
• Specification: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Trademark: HMJ
• Origin: China
• Production Capacity: 200kg/Month

Product Description

Factory Supply Tacrolimus Powder CAS 104987-11-3 Tacrolimus with Best Price

Product Description

 

Tacrolimus CAS 104987-11-3 of Chemical Properties

Melting point     113-115°C
Boiling point     871.7±75.0 °C(Predicted)
density     1.19±0.1 g/cm3(Predicted)
Fp     2ºC
storage temp.     Sealed in dry,Store in freezer, under -20°C
solubility     DMSO: >3 mg/mL
pka    9.97±0.70(Predicted)
form     solid
color     white
Water Solubility     Freely soluble in DMSO or ethanol. Poorly soluble in water.Soluble in dimethyl sulfoxide, ethanol, water, acet one, chloro form, ethyl acet ate, ether, methan ol and dimethyl formamide.
Stability:    Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.
InChIKey    QJJXYPPXXYFBGM-LFZNUXCKSA-N
CAS DataBase Reference    104987-11-3(CAS DataBase Reference)

Function

 

Function and Application of Tacrolimus CAS 104987-11-3

1. Tacrolimus is a macrolide antibiotics. Immunosuppressants. Same mechanism of action as cyclosporine, mainly inhibits the synthesis of interleukin-2. Used for rejection of organ transplants
2. A macrolide that binds to FK506 binding protein (FKBP) to form a complex that reduces peptidyl prolyl isomerase activity in T cells.
3. FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
4. Tacrolimus for use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart.
 

 

 

Related Product

Packaging & Shipping